Mitapivat sulfate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for mitapivat sulfate and what is the scope of freedom to operate?
Mitapivat sulfate
is the generic ingredient in one branded drug marketed by Agios Pharms Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Mitapivat sulfate has one hundred and seventy-four patent family members in forty-five countries.
One supplier is listed for this compound.
Summary for mitapivat sulfate
International Patents: | 174 |
US Patents: | 9 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 12 |
DailyMed Link: | mitapivat sulfate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for mitapivat sulfate
Generic Entry Date for mitapivat sulfate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for mitapivat sulfate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Agios Pharmaceuticals, Inc. | Phase 4 |
Agios Pharmaceuticals, Inc. | Phase 2/Phase 3 |
Agios Pharmaceuticals, Inc. | Phase 3 |
Pharmacology for mitapivat sulfate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2012151451 | ⤷ Try a Trial | |
Finland | C20230017 | ⤷ Try a Trial | |
Philippines | 12017501176 | PYRUVATE KINASE ACTIVATORS FOR USE THERAPY | ⤷ Try a Trial |
Canada | 3088328 | ACTIVATEURS DE LA PYRUVATE KINASE DESTINES A ETRE UTILISES EN THERAPIE (PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY) | ⤷ Try a Trial |
Slovenia | 2448582 | ⤷ Try a Trial | |
European Patent Office | 4285904 | FORMES CRISTALLINES DE N-(4-(4-(CYCLOPROPYLMÉTHYL) PIPÉRAZINE-1-CARBONYL)PHÉNYL)QUINOLÉINE-8-SULFONAMIDE (CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE) | ⤷ Try a Trial |
Japan | 2023160891 | ピルビン酸キナーゼ活性化因子を使用する方法 (METHODS OF USING PYRUVATE KINASE ACTIVATORS) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for mitapivat sulfate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2448582 | CR 2023 00014 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MITAPIVATSULFAT; REG. NO/DATE: EU/1/22/1662 20221110 |
2448582 | LUC00306 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MITAPIVAT SULFATE; AUTHORISATION NUMBER AND DATE: EU/1/22/1662 20221110 |
2448582 | C202330019 | Spain | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR SULFATO DE MITAPIVAT; NATIONAL AUTHORISATION NUMBER: EU/1/22/1662; DATE OF AUTHORISATION: 20221109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1662; DATE OF FIRST AUTHORISATION IN EEA: 20221109 |
2448582 | 2390014-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MITAPIVAT SULFATE; REG. NO/DATE: EU/1/22/1662 20221110 |
2448582 | 122023000025 | Germany | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE MITAPIVATSULFAT; REGISTRATION NO/DATE: EU/1/22/1662 20221109 |
2448582 | CA 2023 00014 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MITAPIVATSULFAT; REG. NO/DATE: EU/1/22/1662 20221110 |
2448582 | 23C1017 | France | ⤷ Try a Trial | PRODUCT NAME: MITAPIVAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE MITAPIVAT, EN PARTICULIER SULFATE DE MITAPIVAT.; REGISTRATION NO/DATE: EU/1/22/1662 20221110 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.